UNSPSC 51152110: Chlordiazepoxide/clidinium

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.

UNSPSC 51152110 Chlordiazepoxide/clidinium is a Commodity code that in recent state and local procurement activity covers the acquisition of pharmaceutical products and drug-related health supplies, though the recent opportunities posted under this code show a significant mismatch with its nominal scope. Seminole County, Florida issued an IFB in June 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually to support community health initiatives, with quarterly deliveries required to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted a Request for Information in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, designed to establish direct contracting relationships between state pharmacy benefit programs and pharmaceutical manufacturers to improve prescription fulfillment and cost management. These opportunities reflect state and local health agencies and county public-health bodies procuring pharmaceutical supplies and pharmacy program administration services.

The code shows minimal geographic concentration across recent activity, with postings from Florida and Texas. The issuing-body mix includes county health departments and state health and human services agencies. However, the recent opportunities posted under this code do not align clearly with chlordiazepoxide/clidinium—a benzodiazepine and anticholinergic combination drug used for gastrointestinal conditions. Seminole County's procurement targets emergency overdose reversal and drug deactivation systems, while Texas HHS's RFI addresses pharmacy benefit program infrastructure and direct-to-manufacturer contracting. The code shows little relevant recent activity for its actual pharmaceutical scope; bidders pursuing work under this code should verify alignment with agency RFP or RFQ language rather than rely on the code classification alone.